Fuchs Endothelial Corneal Dystrophy (FECD) Market Future Scenario, Key Insights, Top Companies 2033

 A recently published study by FMI expects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to augment at a 7.5% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 370 Billion is expected for the market.

Fuchs Endothelial Corneal Dystrophy (FECD) Market


The primary variables impacting the market growth rate include an increase in the prevalence of Fuchs' endothelial corneal dystrophy, an increase in the number of senior persons, and growing healthcare spending.

Get Full Access @ https://www.futuremarketinsights.com/reports/fuchs-endothelial-corneal-dystrophy-fecd-market

Furthermore, advances in medical technology, increased demand for corneal transplantation, and rising attempts by governmental and private organizations to raise awareness about eye disorders and corneal donation are factors that will propel the Fuchs' endothelial corneal dystrophy market forward. An increase in research on cellular treatment techniques and rising demand for eye care would benefit the Fuchs' endothelial corneal dystrophy market during the forecast period.

However, the high expense of therapy and the risks involved with surgical intervention will stifle market expansion. During the projection period, a lack of donor grafts would provide further challenges to Fuchs' endothelial corneal dystrophy market. Because to the presence of leading key players, high disposable income, and sophisticated healthcare infrastructure in this area, North America leads the Fuchs' Endothelial Corneal Dystrophy (FECD) market.

Key Takeaways from the Market Study

  • FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033
  • The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion
  • The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion
  • As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023-2033.
  • North America is expected is expected to grow at a CAGR of 7.4% in the assessment period 2023-2033.
  • Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023-2033.
  • The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market in the forecast period 2023-2033.

 “Asia-Pacific is predicted to rise over the projected period of 2023-2033 due to increased R&D activities, increased investment in the healthcare industry, and more government assistance,” says an analyst at FMI

Market Competition

  • Kowa Pharmaceuticals
  • Trefoil Therapeutics
  • Alcon
  • Emmecell
  • Santen
  • AJL Ophthalmic SA
  • Massachusetts Eye and Ear
  • KeraMed, Inc.
  • Presbia Plc

In May 2022, SEGLENTIS® C-IV is now available for purchase through Kowa Pharmaceuticals America, Inc.

Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey

By Treatment:

  • Phototherapeutic Keratectomy
  • Amniotic Membrane Transplants
  • Anterior Stromal Puncture
  • Conjunctival Flaps

By Diagnosis:

  • Slit-lamp Examination
  • Molecular Genetic Tests
  • Pachymetry

By End User:

  • Hospitals
  • ASCs
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East & Africa

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Clostridium Diagnostics Market in US is anticipated to secure a market value worth US$ 2.7 Billion by 2032 | FMI

Image
  The global Clostridium Diagnostics Market is expected to grow at a CAGR of 12.2% during the forecast period, from US$ 2.5 billion in 2022 to US$ 7.8 billion by 2032. The market grew at a CAGR of 13.6% between 2015 and 2021. The rising prevalence of clostridium-related diseases, as well as increased campaigns to educate people about the condition, are driving the market growth. To learn more about this report @ https://www.futuremarketinsights.com/reports/clostridium-diagnostics-market here has been an increased focus of players in the market to offer vaccines, which can augment the market size in the forecast period. For instance, in March 2022, Japan launched a new center, with a budget of US$ 1.6 Billion, to support vaccine and drug projects as a part of a larger scheme to tackle infectious diseases. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects. Awareness camp...
Read more